FFM
ATXS

Fairmount Funds Management’s Astria Therapeutics ATXS Stock Holding History

Fairmount Funds Management’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,554,129
Closed -$25.9M – 15
2025
Q3 		$25.9M Hold
3,554,129
– – 2.33% 15
2025
Q2 		$19.1M Hold
3,554,129
– – 2.47% 14
2025
Q1 		$19M Hold
3,554,129
– – 2.94% 12
2024
Q4 		$31.8M Hold
3,554,129
– – 3.16% 13
2024
Q3 		$39.1M Hold
3,554,129
– – 3.17% 12
2024
Q2 		$32.3M Hold
3,554,129
– – 3.65% 9
2024
Q1 		$50M Hold
3,554,129
– – 5.45% 7
2023
Q4 		$27.3M Buy
3,554,129
+1,652,732
+87% +$9.14M 2.88% 10
2023
Q3 		$14.2M Hold
1,901,397
– – 1.71% 16
2023
Q2 		$15.8M Hold
1,901,397
– – 2.23% 11
2023
Q1 		$25.3M Hold
1,901,397
– – 4.35% 9
2022
Q4 		$28.3M Buy
1,901,397
+989,661
+109% +$10.2M 4.49% 9
2022
Q3 		$8.24M Hold
911,736
– – 1.45% 22
2022
Q2 		$2.73M Hold
911,736
– – 0.63% 26
2022
Q1 		$6.12M Hold
911,736
– – 1.45% 19
2021
Q4 		$4.91M Hold
911,736
– – 1.62% 19
2021
Q3 		$8.06M Buy
911,736
+229,708
+34% +$2.2M 2.93% 15
2021
Q2 		$8.63M Buy
682,028
+673,167
+7,597% +$8.74M 3.55% 13
2021
Q1 		$154K Buy
+8,861
New +$160K 0.06% 21

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fairmount Funds Management's ATXS Position: Q4 2025 in Review

Fairmount Funds Management sold out of Astria Therapeutics (ATXS) in Q4 2025, closing a stake of 3,554,129 shares — an estimated $25.9M sold.

Fairmount Funds Management first reported a position in ATXS in Q1 2021 and held it in 19 quarters. The position peaked at $50M in Q1 2024. 141 funds tracked by Wall St. Rank hold ATXS as of Q4 2025.

  • Fairmount Funds Management reported no remaining Astria Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Fairmount Funds Management sold 3,554,129 Astria Therapeutics shares in Q4 2025, an estimated $25.9M.
  • Fairmount Funds Management first reported a position in Astria Therapeutics in Q1 2021 and held it in 19 quarters.
  • Fairmount Funds Management's Astria Therapeutics position peaked at $50M in Q1 2024.
  • 141 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2025.

Based on Fairmount Funds Management's 13F filing for Q4 2025, filed 17 Feb 2026.